_This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
Login
| ISBN | 9783030797904 |
|---|---|
| Article number | 9783030797904 |
| Media type | eBook - PDF |
| Copyright year | 2021 |
| Publisher | Springer-Verlag |
| Length | 149 pages |
| Copy protection | Digital watermarking |
